Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1995-06-05
1999-04-20
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
530350, 4352351, 435236, 4241881, 4242081, 4242041, C07K 100, A61K 3900, A61K 3938, C12N 700
Patent
active
058956506
ABSTRACT:
The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. There is also provided a vaccine effective against HIV. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce immunoprotective factors protective against progression of the infection. In another aspect, the vaccine is useful for vaccinating an individual not previously infected with HIV in order to prevent subsequently acquired infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce is antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.
REFERENCES:
patent: 4086134 (1978-04-01), Jarrett
patent: 4591505 (1986-05-01), Prince
patent: 4716102 (1987-12-01), Levy
Baum, "The search for vaccines," Chem. & Engr. News 65:27-34 (1987).
Cease et al., "Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide," Proc. Natl. Acad. Sci. 84:4249-4253 (1987).
Chan et al., "Induction of anti-HIV neutralizing antibodies by synthetic peptides," The EMBO Journal 5:3065-3071 (1986).
Chang et al., Nature 315:151-154 (1985).
Defendi et al., "Oncogenicity by DNA Tumor Viruses: Enhancement after Ultraviolet and Cobalt-60 Radiations," Science 157:703-705 (1967).
Fauci, Proc. Natl. Acad. Sci. USA 83:9278-9283 (1986).
Fischer, "Therapeutic Uses of Intravenous Gammaglobulin for Pediatric Infections," Pediatric Clinics of North America 35:517-533 (1988).
Kennedy et al., "Perspectives on Developing Anti-idiotyp-based Vaccines for Controlling HIV Infection," Gower Acad. J. Ltd., AIDS 1988 2:s119-s127 (1988).
Kennedy et al., "Anti-Idiotypic Antibody Vaccines for Type B Viral Hepatitis in Chimpanzees," Science 232:220-223 (1986).
Koff et al., Science 241:426-432 (1988).
Kramer et al., Science 231:1580-1584 (1986).
Larue et al., "Suitable hollow fiber immunobioreactors for specific ex vivo removal of antibodies and antigens from plasma" Chem Abstracts vol. 103, No. 25, Dec. 23, 1985, abstract No. 212882j.
Marx et al., "Prevention of Simian Acquired Immune Deficiency Syndrome with a Formalin-Inactivated Type D Retrovirus Vaccine," J. of Virology 60:431-435 (1986).
Marx, "Problems with AIDS Vaccines," Science 228:162-165 (1985).
McClelland et al., "Clinical Use of Immunoglobulins," Clinics in Haematology 13:39-69 (1984).
Newmark, "Problems with AIDS Vaccines," Nature 324:304-305 (1986).
Quinnan et al., Transfusion 26(3):481-483 (1986).
Reed et al., J. Cell. Biochem. Suppl. 10A, p. 224, Abs. #D1131 (Jan.-Feb. 1986).
Robert-Guroff et al., "In Vitro Generation of an HTLV-III Variant by Neutralizing Antibody," J. of Immunology 137:3306-3309 (1986).
Salk, Nature 327:473-476 (1987).
Sarngadharan, Cancer Res. (Supplemental) 45:4574-4577 (1985).
Sternberg et al., "Predicitions of antigenic determinants and secondary structures of the major AIDS virus proteins," FEBS Letters 218:231-237 (1987).
Stiehm, "Standard and Special Human Immune Serum Globulins as Therapeutic Agents," Pediatrics 63:301-319 (1979).
Zagury et al., Nature 326:249-250 (1987).
Spine, et al, 1985, "Inactivation of lymphaden-opathy-associated . . . " Lancet Jan. 26, 1985: 188-189.
Carlo Dennis J.
Salk Jonas
Smith Lynette F.
The Immune Response Corporation
LandOfFree
Prevention and treatment of retroviral disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of retroviral disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of retroviral disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2246474